Titelbild

Supervisory Board

 
Portrait

Erich F. Greiner, MD, Cedrus Therapeutics (Chairman)

Erich founded Cedrus Therapeutics Inc. in May 2008 to develop novel therapeutic concepts and medicines. Prior to that, he held various senior positions at Evotec, including Chief Innovation Officer and Member of the Management Team. Prior to joining Evotec, Erich was a Research Associate at the German Research Cancer Center in Heidelberg. He was trained in medicine and molecular biology at the University of Erlangen-Nürnberg and Duke University Medical Center in the US. He serves as a strategic advisor and reviewer for several governmental, public and private institutions in the US and in Europe, including the German Federal Ministry of Education and Research and the Federal Ministry for Health.

 
Portrait

Erich F. Greiner, MD, Cedrus Therapeutics (Chairman)

Erich founded Cedrus Therapeutics Inc. in May 2008 to develop novel therapeutic concepts and medicines. Prior to that, he held various senior positions at Evotec, including Chief Innovation Officer and Member of the Management Team. Prior to joining Evotec, Erich was a Research Associate at the German Research Cancer Center in Heidelberg. He was trained in medicine and molecular biology at the University of Erlangen-Nürnberg and Duke University Medical Center in the US. He serves as a strategic advisor and reviewer for several governmental, public and private institutions in the US and in Europe, including the German Federal Ministry of Education and Research and the Federal Ministry for Health.

 
Portrait

Stefan Herr, PhD, EMBL Ventures

Stefan started EMBL Ventures in 2001. He led several investments in Europe and the US for EMBL Ventures, Heidelberg Innovation and a business angel. Prior to EMBL Ventures, he served as Managing Director of Verivox, a 3i-backed start-up company. Previously Stefan was Vice President at Heidelberg Innovation and Director Cooperations and Licensing at Hagenuk. Stefan earned his PhD in physics from the University of Heidelberg and received additional training in law and business at the University of Hagen. He was a recipient of the Boehringer Ingelheim fellowship and is an alumnus of the European Molecular Biology Laboratory PhD Program.

 
Portrait

Stefan Herr, PhD, EMBL Ventures

Stefan started EMBL Ventures in 2001. He led several investments in Europe and the US for EMBL Ventures, Heidelberg Innovation and a business angel. Prior to EMBL Ventures, he served as Managing Director of Verivox, a 3i-backed start-up company. Previously Stefan was Vice President at Heidelberg Innovation and Director Cooperations and Licensing at Hagenuk. Stefan earned his PhD in physics from the University of Heidelberg and received additional training in law and business at the University of Hagen. He was a recipient of the Boehringer Ingelheim fellowship and is an alumnus of the European Molecular Biology Laboratory PhD Program.

 
Portrait

Sebastian Kreuz, PhD, Boehringer Ingelheim Venture Fund

Sebastian joined the Boehringer Ingelheim Venture Fund (BIVF) in 2019. With over 15 years of experience in translational research and drug discovery within the pharmaceutical industry, he has a strong scientific background in various disease areas and is familiar with a broad range of therapeutic modalities. From 2015 to 2019, he worked in the Research Beyond Borders department at Boehringer Ingelheim (BI) to implement a platform concept for viral vector-based gene therapy as a novel therapeutic modality for BI. During this time, he established a global collaboration network involving collaborations in Europe, China and the US. Before that, Sebastian held a variety of positions within the BI R&D organization. He studied technical biology at the University of Stuttgart and holds a PhD in molecular biology and immunology. In addition to Topas Therapeutics, he serves as a board member for Abalos Therapeutics GmbH, Rewind Therapeutics and Quantro Therapeutics GmbH.

 
Portrait

Sebastian Kreuz, PhD, Boehringer Ingelheim Venture Fund

Sebastian joined the Boehringer Ingelheim Venture Fund (BIVF) in 2019. With over 15 years of experience in translational research and drug discovery within the pharmaceutical industry, he has a strong scientific background in various disease areas and is familiar with a broad range of therapeutic modalities. From 2015 to 2019, he worked in the Research Beyond Borders department at Boehringer Ingelheim (BI) to implement a platform concept for viral vector-based gene therapy as a novel therapeutic modality for BI. During this time, he established a global collaboration network involving collaborations in Europe, China and the US. Before that, Sebastian held a variety of positions within the BI R&D organization. He studied technical biology at the University of Stuttgart and holds a PhD in molecular biology and immunology. In addition to Topas Therapeutics, he serves as a board member for Abalos Therapeutics GmbH, Rewind Therapeutics and Quantro Therapeutics GmbH.

 
Portrait

Marc Lohrmann, Vesalius Biocapital III

Marc is Managing Partner, Vesalius Biocapital III. He has over 20 years of experience and joined Vesalius Biocapital in 2012 as a venture partner. Since then, Marc advised on corporate development and exit of portfolio companies of Fund 1 and Fund 2. He was promoted to Managing Partner for Fund 3 in 2017. Marc started eight lifesciences companies, i.a. co-founded Reverse Medical (acquired by Covidien in 2014), was an investment manager at Bayer Innovation and worked with several corporate finance boutiques focused on life sciences M&A transactions. Marc holds a diploma degree in business administration of the University of Stuttgart-Hohenheim (Germany).

 
Portrait

Marc Lohrmann, Vesalius Biocapital III

Marc is Managing Partner, Vesalius Biocapital III. He has over 20 years of experience and joined Vesalius Biocapital in 2012 as a venture partner. Since then, Marc advised on corporate development and exit of portfolio companies of Fund 1 and Fund 2. He was promoted to Managing Partner for Fund 3 in 2017. Marc started eight lifesciences companies, i.a. co-founded Reverse Medical (acquired by Covidien in 2014), was an investment manager at Bayer Innovation and worked with several corporate finance boutiques focused on life sciences M&A transactions. Marc holds a diploma degree in business administration of the University of Stuttgart-Hohenheim (Germany).

 
Portrait

Bram Vanparys, PhD, Gimv

Bram joined Gimv in 2018. He has over 10 years of international venture capital experience, most recently at Merck Ventures in Amsterdam. Bram has a successful track record in life science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe and Israel, including arGEN-X (ARGX:EBR), Multiplicom (acquired by Agilent), Cartagenia (acquired by Agilent) and Q-Biologicals (acquired by Amatsigroup, now Eurofins). In addition to Topas Therapeutics, he is currently a board member of iSTAR Medical and Imcheck and an observer at Camel-IDs. Bram has a PhD in biotechnology from the University of Ghent (Belgium) and an executive MBA from Vlerick Business School (Belgium).

 
Portrait

Bram Vanparys, PhD, Gimv

Bram joined Gimv in 2018. He has over 10 years of international venture capital experience, most recently at Merck Ventures in Amsterdam. Bram has a successful track record in life science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe and Israel, including arGEN-X (ARGX:EBR), Multiplicom (acquired by Agilent), Cartagenia (acquired by Agilent) and Q-Biologicals (acquired by Amatsigroup, now Eurofins). In addition to Topas Therapeutics, he is currently a board member of iSTAR Medical and Imcheck and an observer at Camel-IDs. Bram has a PhD in biotechnology from the University of Ghent (Belgium) and an executive MBA from Vlerick Business School (Belgium).

 
Portrait

Michael Wacker, PhD, BioMedPartners

Michael is an experienced life science entrepreneur who joined Biomed in 2019. He successfully built up various start-up companies. In addition, he coaches start-ups in Switzerland for Innosuisse, the governmental commission of technology and innovation. Currently he is co-founder and member of the board of directors of Limmatech Biologics, Inura Medical and chairman of the board of Inositec. Previously he was board member and chief business officer of Polyneuron Pharmaceuticals, a spin-off company of the university of Basel. Before joining Polyneuron, he was founder, board member and CSO of GlycoVaxyn, a vaccine development company that was acquired by GSK in 2015 and which valued the company at $212 million. Michael co-founded GlycoVaxyn in 2004 as a spin-off company from the Swiss Federal Institute of Technology Zurich (ETHZ). Michael holds a MSc in biochemistry and completed his PhD and post-doctoral fellowship in microbiology at ETHZ.

 
Portrait

Michael Wacker, PhD, BioMedPartners

Michael is an experienced life science entrepreneur who joined Biomed in 2019. He successfully built up various start-up companies. In addition, he coaches start-ups in Switzerland for Innosuisse, the governmental commission of technology and innovation. Currently he is co-founder and member of the board of directors of Limmatech Biologics, Inura Medical and chairman of the board of Inositec. Previously he was board member and chief business officer of Polyneuron Pharmaceuticals, a spin-off company of the university of Basel. Before joining Polyneuron, he was founder, board member and CSO of GlycoVaxyn, a vaccine development company that was acquired by GSK in 2015 and which valued the company at $212 million. Michael co-founded GlycoVaxyn in 2004 as a spin-off company from the Swiss Federal Institute of Technology Zurich (ETHZ). Michael holds a MSc in biochemistry and completed his PhD and post-doctoral fellowship in microbiology at ETHZ.

 
Portrait

Karl Ziegelbauer, PhD, Bayer AG

Karl Ziegelbauer has been with the Bayer AG since 1993 and currently serves as Head of Open Innovation & Digital Technologies for the Pharmaceutical Division. Karl’s previous positions include: Senior Vice President for the Therapeutic Research Group, Senior Vice President for the Therapeutic Research Group Oncology and Gynecological Therapy, Vice President for Oncology Research, and Vice President for Protein Therapeutics for Bayer Schering Pharma. He also served as Group Leader at Bayer Yakuhin Ltd. in Japan. Prior to joining Bayer, Karl was a Research Fellow at the Max Planck Institute of Biology. Karl holds a PhD in biochemical sciences from the Max Planck Institute of Biology in Germany. He has co-authored more than 60 scientific publications covering topics in basic research as well as drug discovery.

 
Portrait

Karl Ziegelbauer, PhD, Bayer AG

Karl Ziegelbauer has been with the Bayer AG since 1993 and currently serves as Head of Open Innovation & Digital Technologies for the Pharmaceutical Division. Karl’s previous positions include: Senior Vice President for the Therapeutic Research Group, Senior Vice President for the Therapeutic Research Group Oncology and Gynecological Therapy, Vice President for Oncology Research, and Vice President for Protein Therapeutics for Bayer Schering Pharma. He also served as Group Leader at Bayer Yakuhin Ltd. in Japan. Prior to joining Bayer, Karl was a Research Fellow at the Max Planck Institute of Biology. Karl holds a PhD in biochemical sciences from the Max Planck Institute of Biology in Germany. He has co-authored more than 60 scientific publications covering topics in basic research as well as drug discovery.

 
Portrait

Peter Finan, PhD, Epidarex Capital (Observer)

Peter has more than twenty years of experience in drug discovery in the pharmaceutical industry. Prior to joining Epidarex, he was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the United Kingdom. He is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. Earlier in his career, Peter worked at Cancer Research UK and the Yamanouchi Research Institute (now Astellas) and served as Head of Biology at Karus Therapeutics. In addition to Topas Therapeutics, he currently serves on the Board of Directors of Caldan Therapeutics Ltd., Clyde Biosciences Ltd., Enterprise Therapeutics Ltd. and Mironid Ltd. He holds a BSc and PhD in biochemistry and molecular biology from the University of Leeds.

 
Portrait

Peter Finan, PhD, Epidarex Capital (Observer)

Peter has more than twenty years of experience in drug discovery in the pharmaceutical industry. Prior to joining Epidarex, he was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the United Kingdom. He is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. Earlier in his career, Peter worked at Cancer Research UK and the Yamanouchi Research Institute (now Astellas) and served as Head of Biology at Karus Therapeutics. In addition to Topas Therapeutics, he currently serves on the Board of Directors of Caldan Therapeutics Ltd., Clyde Biosciences Ltd., Enterprise Therapeutics Ltd. and Mironid Ltd. He holds a BSc and PhD in biochemistry and molecular biology from the University of Leeds.